

2684 , 0590

BOX PATENT

Attorney Docket No. 24020-X

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Batsheva KEREM

Serial No. 09/871,809

Filed: June 4, 2001

For: **CONTROL OF GENE EXPRESSION**

TRANSMITTAL LETTER


The Commissioner for Patents
Washington, D.C. 20231

Sir:

Submitted herewith for filing in the U.S. Patent and Trademark Office is the following:

- (1) Transmittal Letter
- (2) Information Disclosure Statement
- (3) Information Disclosure Statement Transmittal Letter
- (4) Form PTO-1449 with one (1) reference

Respectfully submitted,
NATH & ASSOCIATES PLLC



Gary M. Nath
Registration No. 26,965
Customer No. 20529

Date: August 27, 2001
NATH & ASSOCIATES PLLC
1030 15TH Street, NW - 6th Floor
Washington, D.C. 20005
GMN/lis:IDS.trans

TECH CENTER 1600/2900

DEC 13 2001

RECEIVED

RECEIVED

AUG 29 2001

Technology Center 2600

RECEIVED


DEC 07 2001

TECH CENTER 1600/2900

RECEIVED

DEC 11 2001

Technology Center 2600



BOX PATENT
Attorney Docket No. 24020-X

#8
LB
1/15/02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Batsheva KEREM

Serial No. 09/871,809

Filed: June 4, 2001

For: CONTROL OF GENE EXPRESSION

INFORMATION DISCLOSURE STATEMENT

Commissioner of Patents
Washington, D.C. 20231

Sir:

Pursuant to Applicant's duty of disclosure under 37 C.F.R. §§1.56 and 1.97-1.99, the documents listed on the attached Form PTO-1449 are being brought to the attention of the Examiner in charge of the above-identified application. No fee is required for this submission because it is submitted before the mailing date of a first Office Action on the merits.

Copies of the documents are attached herewith with a completed Form PTO-1449. The Examiner is respectfully requested to cite the documents listed on the attached Form PTO-1449 in the next Office Action. In so doing, the Examiner is respectfully requested to initial in the space adjacent to the listing of each document on the Form PTO-1449, and return a copy of the initialed Form PTO-1449

RECEIVED

DEC 11 2001

Technology Center 2600

TECH CENTER 1600/2900

DEC 13 2001

RECEIVED

RECEIVED

AUG 29 2001

Technology Center 2600

RECEIVED

DEC 07 2001

TECH CENTER 1600/2900


with the next communication to Applicants, to confirm that these documents have been considered by the Examiner and made of record in this application.

If the Examiner has any questions or wishes to discuss this application, kindly telephone the undersigned at the below-listed number.

Respectfully submitted,


NATH & ASSOCIATES PLLC

Date: August 27, 2001



Gary M. Nath
Registration No. 26,965
Customer No. 20529

NATH & ASSOCIATES
1030 15th Street, NW 6th - Floor
Washington, D.C. 20005
Tel: (202) 775-8383
Fax: (202) 775-8396
(GMN/lis:IDS)



BOX PATENT

Attorney Docket No. 24020-X

THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Batsheva KEREM

Serial No. 09/871,809

Filed: June 4, 2001

For: CONTROL OF GENE EXPRESSION

INFORMATION DISCLOSURE STATEMENT TRANSMITTAL LETTER

Commissioner of Patents
Washington, D.C. 20231

Sir:

An Information Disclosure Statement is submitted herewith pursuant to 37 C.F.R. §1.97-1.98. Please note the following particulars:

[NOTE: One only of items a, b, c, and d must be checked.]
[X] a. The enclosed statement is being filed within three months of the filing date of a national application, or within three months of the date of entry into the national stage as set forth in 37 C.F.R. §1.491 in an international application, or before the mailing date of a first Office Action on the merits, whichever event occurs last.

[] b. The enclosed statement is being filed after a first action on the merits but before the mailing date of a final action under 37 C.F.R. §1.113, or a notice of allowance under 37 C.F.R. §1.311.

The enclosed statement is accompanied by [check one]:


- [] i. a certification in part (e) below as specified in 37 C.F.R. §1.97(e), or
[] ii. a check in the amount of \$180.00 required by

[] c. The enclosed statement is being filed after the mailing date of a final action under 37 C.F.R. §1.113, or a notice of allowance under 37 C.F.R. §1.311, but before payment of the issue fee.

[] d. The enclosed statement is being filed pursuant to 37 C.F.R. §1.97(i), for placement in the file.

[] e. Certification [Check one] [Certification is required only if box (b)(i) or box (c) is checked.]

[] I hereby certify that each item of information contained in the enclosed Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement,



or

[]

I hereby certify that no item of information in the enclosed Information Disclosure Statement herewith was cited in a communication from a foreign patent office in a counterpart foreign application, or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. §1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

or

[]

Appropriate certification is attached.

- [X] f. If no check is enclosed and a fee is due in connection with this communication or if the check enclosed is insufficient, the Commissioner is authorized to charge any fee or additional fee due in connection with this communication to Deposit Account No. 14-0112. A duplicate of this sheet is enclosed.

Copies of the documents are attached herewith with a completed Form PTO-1449. The Examiner is respectfully requested to cite the documents listed on the attached Form PTO-1449 in the next Office Action. In so doing, the Examiner is respectfully requested to initial in the space adjacent to the listing of each document on the Form PTO-1449, and return a copy of the initialed Form PTO-1449 with the next communication to Applicants, to confirm that these documents have been considered by the Examiner and made of record in this application.

If the Examiner has any questions or wishes to discuss this application, kindly telephone the undersigned at the below-listed number.

Respectfully submitted,

NATH & ASSOCIATES PLLCBy: 

Gary M. Nath

Registration No. 26,965

Customer No. 20529

Date: August 27, 2001
NATH & ASSOCIATES PLLC
1030 15th Street, N.W., 6th Floor
Washington, D.C. 20005
GMN/lis (IDS.TRANS)



FORM PTO-1449

INFORMATION DISCLOSURE CITATION

Atty Docket
24002-XSerial No.
09/871,809

Applicant

Batsheva KEREM

Filing Date
June 4, 2001Group Art Unit
2684

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Issue Date	Name	Class	Sub-Class	Filing Date
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

RECEIVED

AUG 29 2001

Technology Center 2600

RECEIVED

DEC 11 2001

Technology Center 2600

TECH CENTER 1000/2600

DEC 07 2001

RECEIVED

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Sub-Class	Translation
	AL						
	AM						
	AN						
	AO						
	AP						

Draw line through citation if not in conformance and not considered.
Include copy of this form with next communication to Applicant.

	AR		Hoffmann, Yvonne, et al., "Htra2-β1 stimulates an exonic splicing enhancer and can restore full-length SMN expression to survival motor neuron 2 (SMN2)." PNAS USA, August 15, 2000, 97(17):9618-9623.
	AS		
	AT		
Examiner			Date Considered
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.			